AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30147355
Drug: Oral methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylnaltrexone 300 mg/day
Trial: 30147355
Drug: Oral methylnaltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methylnaltrexone 450 mg/day
Trial: 25772444
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 30 (control)
Trial: 21211644
Drug: Peptide vaccine
RxNorm normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide vaccine (3 nmol)
Trial: 19411814
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of soy protein containing 160 mg of total isoflavones
Trial: 19411814
Drug: Taste-matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taste-matched placebo (20 g whole milk protein)
Trial: 25303140
Drug: Preventive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive chemotherapy
Trial: 9920356
Drug: Alpha-tocopherol supplementation
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-tocopherol supplementation (50 mg/day)
Trial: 9920356
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (neither alpha-tocopherol nor ASA)
Trial: 8048523
Drug: Rapid inflation
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid inflation (170 ml/s)
Trial: 8048523
Drug: Slow inflation
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow inflation (0.7 ml/s)
Trial: 29088019
Drug: CE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE 0.625 mg alone
Trial: 29088019
Drug: CE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE 0.625 mg/BZA 5 mg
Trial: 29088019
Drug: CE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE 0.625 mg/BZA 10 mg
Trial: 29088019
Drug: CE 0.3
RxNorm normalized name: SODIUM HYALURONATE 0.24 g in 30 mL / PANAX GINSENG FLOWER 0.3 g in 30 mL / ZINC PCA 0.3 g in 30 mL / NIACINAMIDE 2.1 g in 30 mL / GREEN TEA LEAF 0.3 mg in 30 mL / LICORICE 0.3 mg in 30 mL / CHAMOMILE 0.45 mg in 30 mL TOPICAL LIQUID [Niacinamide Soothing Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE 0.3 mg/BZA 20 mg
Trial: 29088019
Drug: CE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE 0.625 mg
Trial: 29088019
Drug: CE 0.3
RxNorm normalized name: SODIUM HYALURONATE 0.24 g in 30 mL / PANAX GINSENG FLOWER 0.3 g in 30 mL / ZINC PCA 0.3 g in 30 mL / NIACINAMIDE 2.1 g in 30 mL / GREEN TEA LEAF 0.3 mg in 30 mL / LICORICE 0.3 mg in 30 mL / CHAMOMILE 0.45 mg in 30 mL TOPICAL LIQUID [Niacinamide Soothing Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CE 0.3 mg with BZA 10 or 20 mg
Trial: 26347109
Drug: Paclitaxel (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (200 mg/m²), carboplatin (AUC 6), bevacizumab (15 mg/kg) with nitroglycerin patches (15 mg, day -2 to +2)
Trial: 26347109
Drug: Paclitaxel (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (200 mg/m²), carboplatin (AUC 6), bevacizumab (15 mg/kg) without nitroglycerin patches
Trial: 16166782
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg prednisolone once daily in the evening
Trial: 2016615
Drug: Levamisole 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole 2.5 mg/kg on 2 consecutive days weekly for 3 years
Trial: 7259869
Drug: Korinfar 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korinfar 30 mg
Trial: 7259869
Drug: Korinfar 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korinfar 50 mg
Trial: 7259869
Drug: Isoptin 120
RxNorm normalized name: Isoptin 120 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoptin 120 mg
Trial: 7259869
Drug: Isoptin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoptin 200 mg
Trial: 7259869
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (Korinfar and Isoptin)
Trial: 30597042
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT2 inhibitor (dapagliflozin: ≤10 mg/day)
Trial: 23664436
Drug: Dabigatran 110
RxNorm normalized name: dabigatran 110 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 110 mg bid
Trial: 23664436
Drug: Dabigatran 150
RxNorm normalized name: dabigatran 150 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 150 mg bid
Trial: 20074388
Drug: Low-fat vegan
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat vegan diet with weekly group meetings
Trial: 17038247
Drug: Enteral nutrition
RxNorm normalized name: ENTERAL NUTRITION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral nutrition (EN) or EN supplemented with parenteral nutrition (EN+PN)
Trial: 2635353
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment only (Control)
Trial: 8878242
Drug: Azithromycin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (n = 341) once daily for 5 days
Trial: 8878242
Drug: Amoxicillin/clavulanate (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (n = 336) three times daily for 10 days
Trial: 8315799
Drug: Epidural buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine (Bn) 0.1-0.2 mg (group B, n = 41)
Trial: 8315799
Drug: Epidural buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine (Bn) 0.1-0.2 mg + 1% lidocaine (group BL, n = 41)
Trial: 8315799
Drug: Epidural buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine (Bn) 0.1-0.2 mg (group B)
Trial: 8315799
Drug: Epidural buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural buprenorphine (Bn) 0.1-0.2 mg + 1% lidocaine (group BL)
Trial: 3788741
Drug: Two 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 400 mg oral doses for a single day
Trial: 3788741
Drug: Three 200
RxNorm normalized name: THREE-LOBE SAGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 200 mg oral doses for three days
Trial: 20664906
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg/day for days 1-10; 300 mg on day 11)
Trial: 17971588
Drug: Cranial radiation
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial radiation therapy (CRT) with double intrathecal (IT) chemotherapy (methotrexate and cytarabine)
Trial: 17971588
Drug: Intensive triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive triple IT chemotherapy (methotrexate, cytarabine and hydrocortisone) without CRT
Trial: 12170410
Drug: 2-l PEG-EL
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-l PEG-EL solution
Trial: 1829439
Drug: High-flux polysulfone
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flux polysulfone (PS) membrane with high heparin regimen (HHR) - 90 IU/kg body weight
Trial: 1829439
Drug: High-flux polyacrylonitrile
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flux polyacrylonitrile (AN 69) membrane with high heparin regimen (HHR) - 90 IU/kg body weight
Trial: 1829439
Drug: High-flux polysulfone
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flux polysulfone (PS) membrane with low heparin regimen (LHR) - 50 IU/kg body weight
Trial: 1829439
Drug: High-flux polyacrylonitrile
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flux polyacrylonitrile (AN 69) membrane with low heparin regimen (LHR) - 50 IU/kg body weight
Trial: 1829439
Drug: Low heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low heparin regimen (LHR)
Trial: 30127374
Drug: Flaxseed consumption
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed consumption (30 g/day) for 12 weeks
Trial: 24633366
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine (batch 1)
Trial: 24633366
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine (batch 2)
Trial: 24633366
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine (batch 3)
Trial: 31977278
Drug: EV71 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EV71 vaccine
Trial: 16039195
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin treatment (short-acting insulin 1 IU.kg(‐1).h(‐1) with 30% glucose 1.5 mL.kg(‐1).h(‐1))
Trial: 16039195
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin treatment
Trial: 16923091
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (saline)
Trial: 9808873
Drug: Recombinant tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant tissue-type plasminogen activator (rt-PA) (100 mg)
Trial: 9808873
Drug: Aspirin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (500 mg i.v. prior to thrombolytic therapy and 325 mg/day orally)
Trial: 7655770
Drug: Oral sulpiride
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sulpiride (2 x 50 mg capsules, 200 mg tablets)
Trial: 7655770
Drug: Intravenous sulpiride
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sulpiride (100 mg)
Trial: 31065111
Drug: Eribulin (1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin (1.4 mg/m² intravenously on day 1 and day 8)
Trial: 31065111
Drug: Dacarbazine (850,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine (850, 1000, or 1200 mg/m² intravenously every 21 days)
Trial: 29797389
Drug: Basal-bolus therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal-bolus therapy (BBT)
Trial: 23095799
Drug: Carvedilol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (10 mg/day)
Trial: 23095799
Drug: ARB (doubled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (doubled dose)
Trial: 23095799
Drug: CCB (doubled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCB (doubled dose)
Trial: 19252451
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g SCE‐A cream (n = 150)
Trial: 17681970
Drug: Ketamine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.15 mg kg(‐1) i.v. 5 min before induction of general anaesthesia
Trial: 16402012
Drug: Johnson's Baby
RxNorm normalized name: Johnson's Baby
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Johnson's Baby products used daily for 8 weeks
Trial: 16402012
Drug: Johnson's Baby
RxNorm normalized name: Johnson's Baby
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Johnson's Baby products used daily for 8 weeks in 186 newborns (92 female plus 94 male) aged 0-4 weeks
Trial: 8599066
Drug: 2-1-1 schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-1-1 schedule (one dose in right arm and one in left arm at day 0, one dose on days 7 and 21)
Trial: 8599066
Drug: Variant schedule
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variant schedule (double dose on day zero and another on day 14)
Trial: 8599066
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses (2-1-1 schedule)
Trial: 2807927
Drug: Urea-containing cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urea-containing cream
Trial: 28349493
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa seeds (5 g daily throughout treatment)
Trial: 25956072
Drug: tiotropium +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiotropium + olodaterol FDC 5/5 μg
Trial: 21593490
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins (5-methyltetrahydrofolate 0.56 mg, vitamins B-6 3 mg, B-12 0.02 mg) and omega-3 fatty acids (eicosapentaenoic and docosahexaenoic acids 600 mg)
Trial: 19912346
Drug: OnabotulinumtoxinA (BOTOX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OnabotulinumtoxinA (BOTOX), maximum 200 units at baseline and month 3, plus oral placebo
Trial: 19912346
Drug: Topiramate (TOPAMAX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (TOPAMAX), 4-week titration to 100 mg/day with option for additional 4-week titration to 200 mg/day, plus placebo saline injections
Trial: 9132744
Drug: Flunisolide (FLUN)
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flunisolide (FLUN) metered dose inhaler 2 x 500 micrograms/d
Trial: 3531315
Drug: sucralfate 2
RxNorm normalized name: sucralfate 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate 2 g 2 i.d. (on waking and at bedtime)
Trial: 3531315
Drug: sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate 1 g 4 i.d. (1/2 h before meals and at bedtime)
Trial: 29330940
Drug: Intralesional steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional steroid injection
Trial: 24211400
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of trabectedin plus pegylated liposomal doxorubicin (PLD)
Trial: 23164667
Drug: Standard procedure
RxNorm normalized name: HOMOSALATE 60 mg in 1 mL / OCTOCRYLENE 30 mg in 1 mL / ZINC OXIDE 80 mg in 1 mL TOPICAL STICK [Standard Procedure Lip Balm SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard procedure (general anesthesia with postoperative morphine treatment)
Trial: 16085588
Drug: F +
RxNorm normalized name: Estroven Menopause Relief + Mood Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F + 0 protocol (immediate administration of radiopharmaceutical after furosemide)
Trial: 16085588
Drug: F -
RxNorm normalized name: F - Fluorine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F - 15 protocol (radiopharmaceutical administered 15 min after furosemide)
Trial: 7546992
Drug: Metoprolol 50-100
RxNorm normalized name: hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol 50-100 mg twice daily
Trial: 7546992
Drug: Xamoterol 100-200
RxNorm normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xamoterol 100-200 mg twice daily
Trial: 6920252
Drug: Dexamethasone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (2 mg/dose) administered 72, 48, and 24 hours before delivery
Trial: 6920252
Drug: Dexamethasone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (2 mg/dose)
Trial: 31652857
Drug: Exergaming intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exergaming intervention (once‐weekly 50‐minute sessions during recess for 8 months)
Trial: 28910200
Drug: 12-g β-alanine
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-g β-alanine (12G)
Trial: 28910200
Drug: 6-g β-alanine
RxNorm normalized name: alanine 6.6 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-g β-alanine (6G)
Trial: 23494053
Drug: 5,000 IU
RxNorm normalized name: bleopmycin 15,000 IU Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5,000 IU unfractionated heparin (UFH)
Trial: 23494053
Drug: 2,500 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2,500 IU low-molecular-weight heparin (LMWH, dalteparin)
Trial: 23494053
Drug: Both heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both heparin types
Trial: 19565734
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with magnetic therapy
Trial: 19565734
Drug: Simple magnetic
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple magnetic therapy (Control)
Trial: 18006969
Drug: Prostate biopsies
RxNorm normalized name: Sus scrofa prostate preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostate biopsies for participants with a prostate specific antigen level of 1.5 ng/ml or more
Trial: 15994145
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg/d orally)
Trial: 9704781
Drug: Epidural bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural bupivacaine, 0.25%, 13 mL
Trial: 8943593
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate 10 mg
Trial: 8582463
Drug: Morphine sulphate
RxNorm normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulphate 15 mg
Trial: 8582463
Drug: Lorazepam 1
RxNorm normalized name: lorazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 1 mg (positive control)
Trial: 350248
Drug: Intravenous labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous labetalol (fast injection)
Trial: 350248
Drug: Intravenous labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous labetalol (slow injection)
Trial: 350248
Drug: Other vasodilator
RxNorm normalized name: Other vasodilators used in cardiac diseases
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other vasodilator hypotensive drugs
Trial: 27310606
Drug: Multisensory stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisensory stimulation therapy (6 sessions of 30 minutes each)
Trial: 15583582
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Polypodium leucotomos (PL) 7.5 mg/kg
Trial: 9164223
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) 1,250 mg/m2 as a 30‐minute intravenous infusion on days 1, 8, and 15 of each 28‐day cycle
Trial: 9164223
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg/m2 on day 1) and Etoposide (80 mg/m2 on days 1, 2, and 3 of each 28‐day cycle)
Trial: 7524907
Drug: G‐CSF (filgrastim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF (filgrastim 5 micrograms/kg/day) administered prior to and after PBSC reinjection
Trial: 7524907
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no G‐CSF prior to leukaphereses or after high‐dose therapy)
Trial: 7524907
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (G‐CSF and control)
Trial: 3109764
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (rt-PA) 80 mg (40 mg, 20 mg, and 20 mg in successive hours)
Trial: 3109764
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (SK) 1.5 million units over 1 hr
Trial: 2959716
Drug: Intravenous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tissue plasminogen activator (rt-PA)
Trial: 2868337
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (SK)
Trial: 26291080
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg E-52862
Trial: 26291080
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg E-52862
Trial: 26291080
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg E-52862
Trial: 20628233
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg zoledronic acid infusions (monthly, bi-monthly, tri-monthly, or semestral)
Trial: 12728462
Drug: Iodine restriction
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine restriction (less than 100 micro g/day)
Trial: 10915728
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta (6 million units, twice a week for 36 months)
Trial: 10915728
Drug: No IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No IFN therapy (control group)
Trial: 8725871
Drug: Ergoset (1.6-2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergoset (1.6-2.4 mg/day)
Trial: 1483671
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg in saline solution